Home> Products> managing type 2 diabetes mellitus

{ "products": [ { "_id": "68e7a474f3481c1f16d3b038", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin (50mg), Metformin Hydrochloride (500mg) & Glimepiride (2mg)", "description": "Sitagliptin 50mg, Metformin Hydrochloride 500mg & Glimepiride 2mg is a combination oral medication designed for the effective management of type 2 diabetes mellitus. This triple-action formula works synergistically to control blood glucose levels by addressing insulin resistance, enhancing insulin secretion, and regulating post-meal sugar spikes. Ideal for patients who require more than one mechanism to maintain stable blood sugar, this combination is often prescribed when monotherapy or dual therapy is insufficient.\n\nUses\n\nManagement of Type 2 Diabetes Mellitus in adults.\n\nHelps in controlling fasting and postprandial blood glucose levels.\n\nRecommended for patients whose blood sugar is not adequately controlled with a single antidiabetic medicine.\n\nCan be used as part of a comprehensive diabetes management plan, including diet and exercise.\n\nKey Benefits\n\nDual Mechanism Control:\n\nMetformin Hydrochloride reduces hepatic glucose production and improves insulin sensitivity.\n\nGlimepiride stimulates pancreatic beta cells to secrete more insulin.\n\nSitagliptin enhances incretin hormones, leading to better regulation of post-meal glucose levels.\n\nEffective Blood Sugar Management:\nHelps maintain optimal fasting and postprandial glucose levels, reducing the risk of diabetes-related complications.\n\nConvenient Combination Therapy:\nCombines three mechanisms in a single tablet, reducing the pill burden and improving patient compliance.\n\nSupports Overall Health:\nHelps prevent long-term complications such as neuropathy, nephropathy, retinopathy, and cardiovascular risks associated with diabetes.\n\nPossible Side Effects\n\nWhile generally well-tolerated, some patients may experience:\n\nGastrointestinal issues: nausea, vomiting, diarrhea, or abdominal discomfort (mainly from Metformin).\n\nHypoglycemia (low blood sugar): more likely due to Glimepiride; symptoms include dizziness, sweating, or shakiness.\n\nAllergic reactions: rash, itching, or swelling in rare cases.\n\nOther mild effects: headache, fatigue, or minor changes in taste.\n\nNote: Patients should always consult their doctor before starting this combination and report any unusual symptoms immediately.\n\nConclusion\n\nThe Sitagliptin, Metformin Hydrochloride & Glimepiride combination provides a powerful, multi-targeted approach to managing type 2 diabetes. By tackling high blood sugar from different angles, it supports better glucose control, enhances overall quality of life, and reduces the risk of diabetes-related complications. When used alongside proper diet, exercise, and medical guidance, this combination can be a cornerstone in effective diabetes management.", "price": 180.0, "discountamount": 54.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2185, "imageuri": "https://productimages.withfloats.com/actual/68e7a47b040520d37b5e6b34.png", "tileimageuri": "https://productimages.withfloats.com/tile/68e7a47b040520d37b5e6b34.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-10-09T12:03:00.012Z", "updatedon": "2025-10-09T12:03:00.012Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-50mg-metformin-hydrochloride-500mg-glimepiride-2mg-/2185", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35c945c5e728a14d08ad8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin (25mg), Linagliptin (5mg)", "description": "GLIEMPAFLOZIN LINA 25mg/5mg is a combination medication designed for individuals managing type 2 diabetes mellitus. It contains Empagliflozin (25mg) and Linagliptin (5mg), two potent anti-diabetic agents that work together to control blood sugar levels effectively. This medication is typically prescribed to patients who require dual therapy to achieve optimal glycemic control when diet and exercise alone are insufficient.\n\n \nKey Benefits :\n \n\nEffective Blood Sugar Control: Regulates blood glucose levels efficiently in patients with type 2 diabetes.\n\nWeight Management: Empagliflozin promotes weight loss by removing excess glucose from the body.\n\nHeart and Kidney Benefits: Shown to provide cardiovascular and renal protection, reducing the risk of heart failure.\n\nLower Risk of Hypoglycemia: Minimal chances of low blood sugar episodes compared to other anti-diabetic medications.\n\nConvenient Dual Therapy: Combines two complementary mechanisms for enhanced glycemic control in a single tablet.\n\n \nHow Does It Work?\n \n\nEmpagliflozin (SGLT2 Inhibitor): This component blocks Sodium-Glucose Cotransporter-2 (SGLT2) in the kidneys, preventing glucose reabsorption and facilitating its elimination through urine. This leads to a significant reduction in blood sugar levels.\n\nLinagliptin (DPP-4 Inhibitor): It inhibits Dipeptidyl Peptidase-4 (DPP-4) enzyme, which increases incretin hormone levels. This enhances insulin secretion and suppresses glucagon production, leading to better post-meal glucose control.\n\n \nDirections for Use\n \n\nTake one tablet daily, preferably at the same time each day.\n\nSwallow the tablet whole with water, with or without food.\n\nFollow the dosage regimen prescribed by your healthcare provider.\n\nRegular monitoring of blood sugar levels is recommended.\n\n \nSide Effects\n \n\nAlthough GLIEMPAFLOZIN LINA 25mg/5mg is generally well-tolerated, some patients may experience:\n\nFrequent Urination: Due to glucose excretion through urine.\n\nDehydration or Thirst: Increased urination may lead to mild dehydration.\n\nUrinary Tract Infections (UTIs): A common side effect associated with SGLT2 inhibitors.\n\nNasal Congestion or Sore Throat: Occasionally observed with DPP-4 inhibitors.\n\nGastrointestinal Discomfort: Mild nausea or diarrhea in some cases.\n\nHypotension (Low Blood Pressure): Especially in patients with pre-existing conditions.\n\n ", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "urine dehydration", "preexisting conditions", "generally welltolerated", "food follow", "day swallow", "significant reduction", "single tablet", "complementary mechanisms", "provide cardiovascular", "body heart", "linagliptin 5mg", "empagliflozin 25mg", "glucose excretion", "typically prescribed", "tablet daily preferably", "combination medication designed", "dosage regimen prescribed", "removing excess glucose", "common side effect", "thirst increased urination", "gliempaflozin lina 25mg5mg", "recommended side effects", "blood sugar levels", "enhances insulin secretion", "enhanced glycemic control", "hypoglycemia minimal chances", "renal protection reducing", "kidney benefits shown", "require dual therapy", "potent antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2048, "imageuri": "https://productimages.withfloats.com/actual/67a35cb9b07d7c125c0f536d.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35cb9b07d7c125c0f536d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:41:56.39Z", "updatedon": "2025-03-17T11:04:56.55Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25mg-linagliptin-5mg-/2048", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN LINA 25mg/ 5mg", "category": "DIABETIC RANGE", "tags": [ "empagliflozin-linagliptin 25-5 mg price", "Empagliflozin and Linagliptin brands in India", "empagliflozin-linagliptin 10-5 mg", "Fixed dose combination of Empagliflozin and Linagliptin Tablets Price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "665dabdd8ecffe165c34f6cd", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ACARBZONE 25 ", "description": "ACARBZONE 25 \nAcarbose (25mg)\nIntroduction to ACARBZONE 25\nACARBZONE 25 contains Acarbose 25mg, a medication used primarily for managing type 2 diabetes mellitus. Acarbose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing down the digestion and absorption of carbohydrates in the intestines. This medication is typically used in combination with diet, exercise, and other antidiabetic medications to improve glycemic control in adults with type 2 diabetes.\n\nWhat is Acarbose?\nOverview of Acarbose\nAcarbose is an antidiabetic drug that works by inhibiting enzymes in the intestines responsible for breaking down carbohydrates into glucose. By slowing down this process, Acarbose helps prevent spikes in blood sugar levels after meals, providing better overall blood glucose control.\n\nMechanism of Action\nAlpha-Glucosidase Inhibition: Acarbose inhibits the alpha-glucosidase enzymes in the small intestine, which are necessary for the breakdown of complex carbohydrates into simple sugars.\nDelayed Carbohydrate Absorption: By slowing down carbohydrate digestion, Acarbose reduces the postprandial (after-meal) increase in blood glucose levels, helping to maintain more stable blood sugar levels throughout the day.\nBenefits of ACARBZONE 25\nEffective Blood Sugar Management\nPostprandial Glucose Control: ACARBZONE 25 helps reduce the spikes in blood sugar levels that occur after meals, which is crucial for effective diabetes management.\nComplementary Therapy: Acarbose can be used alongside other antidiabetic medications, such as metformin or insulin, to enhance overall glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: ACARBZONE 25 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, Acarbose can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Acarbose may help with weight management as it slows carbohydrate absorption, potentially leading to reduced caloric intake.\nImproved Digestive Health: The slowed digestion process can also benefit overall digestive health by reducing the strain on the digestive system.\nHow to Use ACARBZONE 25\nDosage and Administration\nRecommended Dosage: The typical starting dose of ACARBZONE 25 is one 25mg tablet taken three times daily, at the start of each main meal. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet with the first bite of each main meal. This timing helps maximize the effectiveness of Acarbose in controlling postprandial blood sugar levels.\nGuidelines for Optimal Use\nConsistent Use: For best results, take ACARBZONE 25 consistently as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/acarbzone-25-133412", "price": 80.5, "discountamount": 24.15, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "diet", "Order", "EMAIL", "meals", "adults", "spikes", "Action", "timing", "strain", "insulin", "Support", "Overview", "increase", "readings", "patients", "metformin", "main meal", "breakdown", "Mechanism", "ACARBZONE", "neuropathy", "first bite", "Guidelines", "intestines", "Optimal Use", "information", "Adjustments", "retinopathy", "combination", "sterispharma", "Introduction", "Reduced Risk", "best results", "CALL/WHATSAPP", "effectiveness", "Acarbose 25mg", "simple sugars", "Consistent Use", "Administration", "treatment plan", "caloric intake", "one 25mg tablet", "small intestine", "digestive system", "Exercise Adjunct", "digestion process", "antidiabetic drug", "excellent adjunct", "Weight Management", "Recommended Dosage", "healthcare provider", "blood sugar control", "individual response", "blood glucose levels", "Complementary Therapy", "typical starting dose", "complex carbohydrates", "carbohydrate digestion", "cardiovascular disease", "long-term complications", "lifestyle modifications", "overall glycemic control", "overall digestive health", "type 2 diabetes mellitus", "Improved Digestive Health", "alpha-glucosidase enzymes", "stable blood sugar levels", "Additional Health Benefits", "alpha-glucosidase inhibitor", "Alpha-Glucosidase Inhibition", "Postprandial Glucose Control", "effective diabetes management", "overall blood glucose control", "other antidiabetic medications", "Delayed Carbohydrate Absorption", "postprandial blood sugar levels", "Effective Blood Sugar Management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1239, "imageuri": "https://productimages.withfloats.com/actual/665dabdf3b5550f17788ba29.png", "tileimageuri": "https://productimages.withfloats.com/tile/665dabdf3b5550f17788ba29.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-03T11:41:17.118Z", "updatedon": "2024-06-03T11:47:42.657Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/acarbzone-25-/1239", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ACARBZONE 25 ", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "662f59fbe6d2b71ee071f9c3", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIMITERIS TRIO 0.2 ", "description": "GLIMITERIS TRIO 0.2 \nVoglibose 0.2 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg\nGLIMITERIS TRIO 0.2 is a combination medication containing Voglibose 0.2 mg, Glimepiride 3 mg, and Metformin Hydrochloride 500 mg. It is commonly prescribed for managing blood sugar levels in patients with type 2 diabetes mellitus. Voglibose helps reduce post-meal glucose spikes by inhibiting carbohydrate absorption in the intestine. Glimepiride stimulates insulin release from the pancreas, aiding glucose utilization by cells. Metformin improves insulin sensitivity and reduces liver glucose production. This triple action helps control blood sugar effectively. It is important to follow your healthcare provider's dosage instructions and monitor blood glucose levels regularly while using GLIMITERIS TRIO 0.2.\nFor further information:\nEmail: info@sterispharma.com / contact@sterispharma.com\nCall/WhatsApp: 7877551268, 7849827488\nORDER Now: \n\n", "price": 155.0, "discountamount": 46.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "cells", "0.2 mg", "patients", "pancreas", "intestine", "Voglibose", "Glimepiride", "triple action", "GLIMITERIS TRIO", "insulin release", "blood sugar levels", "dosage instructions", "insulin sensitivity", "glucose utilization", "healthcare provider", "blood glucose levels", "combination medication", "carbohydrate absorption", "Metformin Hydrochloride", "liver glucose production", "post-meal glucose spikes", "type 2 diabetes mellitus" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 798, "imageuri": "https://productimages.withfloats.com/actual/662f59fd670596731f8ef7a6.png", "tileimageuri": "https://productimages.withfloats.com/tile/662f59fd670596731f8ef7a6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-04-29T08:27:39.128Z", "updatedon": "2024-06-12T13:00:06.306Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimiteris-trio-0-2-/798", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Voglibose 0.2 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg", "category": "DIABETICSRANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68822dd35b399ba6097ed11b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET G 0.5 FORTE", "description": "SEIZMET G0.5 FORTE is a powerful oral antidiabetic medication formulated with a combination of glimepiride and metformin hydrochloride. This dual-action therapy is specifically designed for patients with type 2 diabetes mellitus who are unable to control their blood sugar levels with diet and exercise alone. The combination works in synergy to manage blood glucose effectively, reduce insulin resistance, and improve overall glycemic control.\n\nGlimepiride and metformin hydrochloride tablets are a combination medication used to treat type 2 diabetes. They work by helping the pancreas release more insulin and by reducing the amount of sugar produced by the liver, while also making the body more sensitive to insulin.\n\nWhat is SEIZMET G0.5 FORTE?\nSEIZMET G0.5 FORTE contains two active ingredients:\n\nGlimepiride (0.5 mg): A sulfonylurea class drug that stimulates the beta cells of the pancreas to release insulin.\n\nMetformin Hydrochloride: A biguanide that works primarily by suppressing hepatic glucose production and increasing insulin sensitivity in muscles.\n\nTogether, this combination addresses both insulin deficiency and resistance—two key factors in type 2 diabetes.\n\nUses of SEIZMET G0.5 FORTE:\n\nEffective in managing type 2 diabetes mellitus\n\nHelps in reducing fasting and postprandial blood glucose levels\n\nUsed as monotherapy or in combination with other antidiabetic agents\n\nReduces the risk of diabetic complications such as nephropathy, retinopathy, and cardiovascular disease\n\nSide Effects of SEIZMET G0.5 FORTE:\nLike all medications, glimepiride and metformin hydrochloride tablets may cause side effects in some patients. Common side effects include:\n\nNausea or vomiting\n\nDiarrhea\n\nHypoglycemia (low blood sugar)\n\nHeadache\n\nDizziness\n\nMetallic taste in the mouth\n\nAbdominal discomfort\n\nIn rare cases, it may cause lactic acidosis, a serious condition related to metformin accumulation.\n\nPrecautions Before Using SEIZMET G0.5 FORTE:\n\nAlways take the medication exactly as prescribed by your doctor.\n\nInform your physician if you have a history of liver or kidney disorders, heart disease, or alcohol abuse.\n\nAvoid excessive alcohol consumption while on this medication as it increases the risk of lactic acidosis.\n\nNot recommended for patients with type 1 diabetes or diabetic ketoacidosis.\n\nRegularly monitor your blood sugar and kidney function.\n\nThis medicine should be used during pregnancy only if absolutely necessary and under medical supervision.\n\nDrug Interactions: What Drugs Interact with SEIZMET G0.5 FORTE?\nCertain medications can interact with glimepiride and metformin, affecting their efficacy or increasing the risk of side effects. These include:\n\nBeta-blockers (e.g., propranolol) – may mask hypoglycemia symptoms\n\nDiuretics – may impair blood sugar control\n\nACE inhibitors – may increase the blood glucose-lowering effect\n\nCorticosteroids – may reduce the effectiveness of the medication\n\nAntipsychotics (e.g., olanzapine)\n\nAlcohol – increases the risk of lactic acidosis\n\nCimetidine – may raise metformin levels in the body\n\nAlways inform your healthcare provider about all medications, supplements, or herbal products you are taking.\n\nConclusion:\nSEIZMET G0.5 FORTE is a trusted, effective choice for managing type 2 diabetes, offering the combined benefits of glimepiride and metformin hydrochloride tablets. With dual mechanisms—enhancing insulin secretion and improving insulin sensitivity—it delivers comprehensive glycemic control. When taken as directed and with regular monitoring, SEIZMET G0.5 FORTE can be a valuable part of a diabetic patient’s treatment regimen, contributing to a healthier, more balanced life.\n\nFor best results, pair this medication with a proper diet, regular physical activity, and periodic blood glucose testing. Always consult your healthcare provider for personalized advice.", "price": 125.0, "discountamount": 38.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2151, "imageuri": "https://productimages.withfloats.com/actual/68822dd8296c4d19d55e8535.png", "tileimageuri": "https://productimages.withfloats.com/tile/68822dd8296c4d19d55e8535.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-07-24T12:57:55.385Z", "updatedon": "2025-07-24T12:57:55.385Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-g-0-5-forte/2151", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "glimepiride and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "glimepiride and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6842b8014256f7114dfbd884", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "Trelagliptin 100mg in TRELAQWK 100 is an innovative once-weekly oral medication formulated with Trelagliptin 100mg, specifically designed to support adults in managing type 2 diabetes mellitus (T2DM). As a member of the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, it provides a simplified and effective approach to improving glycemic control when combined with a healthy diet and regular exercise. Its weekly dosing schedule enhances treatment adherence, offering a more sustainable option for long-term diabetes care.\n\nActive Ingredient:\nTrelagliptin 100mg\nA potent, long-acting DPP-4 inhibitor that helps maintain stable blood glucose levels by preserving incretin activity. Incretins are natural hormones that promote insulin release and suppress glucagon, playing a vital role in blood sugar regulation.\n\nCore Benefits:\nConvenient once-weekly dosing enhances patient compliance\n\nEffectively lowers both fasting and postprandial (after-meal) blood sugar\n\nPromotes natural insulin production without contributing to weight gain\n\nCarries a low risk of hypoglycemia, especially when not used with insulin\n\nCan be used alone or in combination with other antidiabetic medications like metformin or sulfonylureas\n\nMechanism of Action:\nTRELAQWK 100 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These hormones play a crucial role in regulating blood sugar after meals. By prolonging their activity, Trelagliptin enhances insulin secretion and reduces glucagon levels, resulting in improved glycemic control. Its extended half-life allows for once-a-week administration, setting it apart from daily DPP-4 inhibitors.\n\nDosage & Administration:\nRecommended Dose: One tablet per week, or as advised by your doctor\n\nHow to Take: With or without food, preferably on the same day each week\n\nIf a dose is missed, do not double the next dose; seek guidance from your healthcare provider\n\nPossible Side Effects:\nTRELAQWK 100 is generally safe and well-tolerated. Some individuals may experience:\n\nHeadache\n\nNasopharyngitis (mild cold symptoms)\n\nConstipation\n\nUpper respiratory tract infections\n\nRare allergic reactions such as rashes or skin irritation\n\nSeek immediate medical advice if you experience unusual symptoms such as severe abdominal pain, persistent skin reactions, or signs of pancreatitis.", "price": 3.0, "discountamount": 1.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "medical advice", "generally safe", "healthcare provider", "food preferably", "extended halflife", "crucial role", "dpp4 enzyme", "sulfonylureas mechanism", "antidiabetic medications", "low risk", "vital role", "sustainable option", "regular exercise", "healthy diet", "effective approach", "support adults", "trelaqwk 100trelaqwk 100", "hormones play", "natural hormones", "dose seek guidance", "promote insulin release", "degrades incretin hormones", "experience unusual symptoms", "skin irritation seek", "onceaweek administration setting", "improved glycemic control", "regulating blood sugar", "weight gain carries", "suppress glucagon playing", "improving glycemic control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2132, "imageuri": "https://productimages.withfloats.com/actual/6842b80c8a53ae8db15a02ac.png", "tileimageuri": "https://productimages.withfloats.com/tile/6842b80c8a53ae8db15a02ac.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-06T09:42:25.371Z", "updatedon": "2025-06-11T11:17:09.096Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2132", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Trelagliptin 100mg", "category": "DIABETIC RANGE", "tags": [ "Trelagliptin side effects", "Trelagliptin brand name", "Trelagliptin brands in India", "Trelagliptin uses", "Trelagliptin 100mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }